VORLADIQ Trademark

Trademark Overview

On Sunday, June 9, 2019, a trademark application was filed for VORLADIQ with the United States Patent and Trademark Office. The USPTO has given the VORLADIQ trademark a serial number of 88465342. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Monday, September 19, 2022. This trademark is owned by Pfizer Inc.. The VORLADIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
vorladiq

General Information

Serial Number88465342
Word MarkVORLADIQ
Filing DateSunday, June 9, 2019
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateMonday, September 19, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 6, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateMonday, September 19, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, September 19, 2022ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Monday, September 19, 2022ABANDONMENT - AFTER PUBLICATION
Friday, September 16, 2022TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, February 22, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, February 19, 2022SOU EXTENSION 5 GRANTED
Friday, February 11, 2022SOU EXTENSION 5 FILED
Friday, February 18, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 11, 2022TEAS EXTENSION RECEIVED
Friday, September 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 1, 2021SOU EXTENSION 4 GRANTED
Wednesday, September 1, 2021SOU EXTENSION 4 FILED
Wednesday, September 1, 2021TEAS EXTENSION RECEIVED
Wednesday, March 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 1, 2021SOU EXTENSION 3 GRANTED
Monday, March 1, 2021SOU EXTENSION 3 FILED
Monday, March 1, 2021TEAS EXTENSION RECEIVED
Wednesday, September 2, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 31, 2020SOU EXTENSION 2 GRANTED
Monday, August 31, 2020SOU EXTENSION 2 FILED
Monday, August 31, 2020TEAS EXTENSION RECEIVED
Wednesday, February 26, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 24, 2020SOU EXTENSION 1 GRANTED
Monday, February 24, 2020SOU EXTENSION 1 FILED
Monday, February 24, 2020TEAS EXTENSION RECEIVED
Monday, February 24, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, February 24, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, February 21, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, February 21, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, February 21, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, February 21, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 21, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, October 1, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 6, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 6, 2019PUBLISHED FOR OPPOSITION
Wednesday, July 17, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, June 22, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, June 22, 2019ASSIGNED TO EXAMINER
Friday, June 21, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Wednesday, June 12, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

vorladiq preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological